Lepu Biopharma Co., Ltd.

2157

CNE100004SM4

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
5.04 ^HKD	+7.23%		+16.94%	+19.71%

Apr. 12	Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	MT
Mar. 27	Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Lepu Biopharma Co., Ltd.(SEHK:2157) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Lepu Biopharma Co., Ltd.

Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	Apr. 11	MT
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation	Mar. 10	MT
Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer	Mar. 10	CI
Lepu Biopharma Shareholders to Vote Jan. 31 on Contract to Produce Drugs for Lepu Medical Technology	Jan. 17	MT
Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC	Dec. 28	CI
Lepu Biopharma Completes Patient Enrollment for Phase 2B Trial for Nasopharyngeal Cancer Drug	Dec. 28	MT
Lepu Biopharma Renews Procurement Agreement With Lepu Medical Technology	Dec. 26	MT
Lepu Biopharma Gets US FDA's Orphan Drug Designation for Pancreatic Cancer Drug	Dec. 14	MT
Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer	Dec. 14	CI
US FDA Grants Fast Track Designation to Lepu Biopharma's Anti-Cancer Drug	Dec. 04	MT
Lepu Biopharma to Provide Drug Production Services to Lepu Medical Technology	Nov. 14	MT
Lepu Biopharma Divests 15% Stake in Technical Services Provider	23-09-28	MT
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	23-09-28	CI
Lepu Biopharma Co., Ltd.(SEHK:2157) added to S&P Global BMI Index	23-09-18	CI
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Lepu Biopharma Seeks to Extend Validity of Secondary Listing in Shanghai	23-08-09	MT
Stocks add to rebound; SSE ups earnings guidance	23-03-30	AN
AstraZeneca Completes KYM Solid Tumors Treatment Deal	23-03-30	DJ
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901	23-02-23	CI
Keymed, Lepu Biopharma JV Signs License Deal with AstraZeneca for Cancer Treatment	23-02-22	MT
Certain H Shares of Lepu Biopharma Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-FEB-2023.	23-02-22	CI
Lepu Biopharma Presents Phase 1A Trial Results at Cancer Symposium	23-02-07	MT
Lepu Biopharma Co., Ltd. Provides Update on the Data from Phase Ia Clinical Study of CMG901	23-02-05	CI

Chart Lepu Biopharma Co., Ltd.

Duration

Period

More charts

LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Companyâs major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lepu Biopharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.665 CNY

Average target price

3.403 CNY

Spread / Average Target

-27.06%

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEPU BIOPHARMA CO., LTD.	+19.71%	1.07B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs